Olezarsen, an antisense oligonucleotide that targets the mRNA for apolipoprotein C-III, reduced triglycerides (TGs) in patients with severe hypertriglyceridemia (sHTG, TG >500 mg/dL) by 50-72% at 6 months in two double-blinded placebo-controlled randomized clinical trials (RCTs, CORE-TIMI 72a, CORE2-TIMI 72b)....
R. Giugliano, N. Marston, B. Bergmark et al.· European Heart Journal· 0 citations
Single subcutaneous doses of ION775 produced rapid, significant, dose-dependent, and durable reductions in apoC-III and TGs, with favorable effects on atherogenic lipoprotein measures and an acceptable safety profile through up to 12 months of follow-up.
S. Tsimikas, E. Morgan, J. Sharma et al.· European Heart Journal· 0 citations
BACKGROUND
Apolipoprotein C-III (apoC-III) regulates triglyceride-rich lipoprotein metabolism. ION775 is a GalNAc-conjugated small interfering RNA designed to silence APOC3 mRNA and enable infrequent dosing.
OBJECTIVE
To evaluate the safety, tolerability, and lipid effects of single-dose ION775 in adults with moderat...
S. Tsimikas, Erin S. Morgan, Jyoti Sharma et al.· Journal of Clinical Lipidolo...· 0 citations
Olezarsen reduced triglycerides across the hypertriglyceridemia spectrum, with greater effects in patients on background fibrates, particularly with diabetes, to support potential complementary mechanisms and further investigation of concomitant triglyceride-reducing therapy.
Annabel Z. Wang, V. Alexander, T. Prohaska et al.· Journal of Clinical Lipidolo...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.